Monopar Therapeutics (MNPR)
Market Price (5/12/2026): $65.86 | Market Cap: $562.0 MilSector: Health Care | Industry: Biotechnology
Monopar Therapeutics (MNPR)
Market Price (5/12/2026): $65.86Market Cap: $562.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.6, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.7% Key risksMNPR key risks include [1] a history of clinical trial failure with its Validive program and [2] significant competitive threats to its lead asset, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.6, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.7% |
| Key risksMNPR key risks include [1] a history of clinical trial failure with its Validive program and [2] significant competitive threats to its lead asset, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Monopar Therapeutics (MNPR) stock has gained about 10% since 1/31/2026 because of the following key factors:
1. Positive Phase 3 Clinical Trial Results and Planned NDA Submission for ALXN1840.
Monopar Therapeutics announced on April 19, 2026, new analyses from its randomized controlled Phase 3 FoCus trial of ALXN1840 for Wilson disease, demonstrating greater neurologic benefit compared to standard of care. Specifically, clinically meaningful neurologic worsening at Week 48 was observed in only 9% of ALXN1840-treated patients versus 25% of patients on standard of care (p=0.038). These positive results support the company's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in mid-2026.
2. Advancement of MNPR-101 Radiopharmaceutical Programs.
The company reported Investigational New Drug (IND) clearance for MNPR-101-Lu, a therapeutic radiopharmaceutical for advanced cancers, to initiate a Phase 1 clinical trial in the US. This development was highlighted in Monopar's fourth quarter and full-year 2025 financial results, released on March 27, 2026, emphasizing the continued development of its MNPR-101 programs. A Phase 1a clinical trial for MNPR-101-Lu is already active and recruiting in Australia for patients with advanced cancers.
Show more
1. Positive Phase 3 Clinical Trial Results and Planned NDA Submission for ALXN1840.
Monopar Therapeutics announced on April 19, 2026, new analyses from its randomized controlled Phase 3 FoCus trial of ALXN1840 for Wilson disease, demonstrating greater neurologic benefit compared to standard of care. Specifically, clinically meaningful neurologic worsening at Week 48 was observed in only 9% of ALXN1840-treated patients versus 25% of patients on standard of care (p=0.038). These positive results support the company's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in mid-2026.
2. Advancement of MNPR-101 Radiopharmaceutical Programs.
The company reported Investigational New Drug (IND) clearance for MNPR-101-Lu, a therapeutic radiopharmaceutical for advanced cancers, to initiate a Phase 1 clinical trial in the US. This development was highlighted in Monopar's fourth quarter and full-year 2025 financial results, released on March 27, 2026, emphasizing the continued development of its MNPR-101 programs. A Phase 1a clinical trial for MNPR-101-Lu is already active and recruiting in Australia for patients with advanced cancers.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 8.5% change in MNPR stock from 1/31/2026 to 5/11/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 60.38 | 65.52 | 8.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 7 | 9 | -16.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/11/2026| Return | Correlation | |
|---|---|---|
| MNPR | 8.5% | |
| Market (SPY) | 3.6% | 42.9% |
| Sector (XLV) | -7.2% | 24.3% |
Fundamental Drivers
The -24.0% change in MNPR stock from 10/31/2025 to 5/11/2026 was primarily driven by a -18.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 86.16 | 65.52 | -24.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 7 | 9 | -18.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| MNPR | -24.0% | |
| Market (SPY) | 5.5% | 26.5% |
| Sector (XLV) | -0.0% | 26.6% |
Fundamental Drivers
The 56.7% change in MNPR stock from 4/30/2025 to 5/11/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 41.82 | 65.52 | 56.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 5 | 9 | -42.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| MNPR | 56.7% | |
| Market (SPY) | 30.4% | 21.2% |
| Sector (XLV) | 3.6% | 13.2% |
Fundamental Drivers
The 1064.7% change in MNPR stock from 4/30/2023 to 5/11/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.63 | 65.52 | 1064.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 3 | 9 | -69.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/11/2026| Return | Correlation | |
|---|---|---|
| MNPR | 1064.7% | |
| Market (SPY) | 78.7% | 6.6% |
| Sector (XLV) | 12.6% | 1.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MNPR Return | -48% | -26% | -86% | 1193% | 197% | -3% | 108% |
| Peers Return | -7% | 32% | 41% | -1% | 2% | 2% | 78% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| MNPR Win Rate | 17% | 33% | 17% | 42% | 67% | 20% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 67% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| MNPR Max Drawdown | -48% | -55% | -88% | -9% | 0% | -23% | |
| Peers Max Drawdown | -25% | 0% | -2% | -3% | -23% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, AVLN, DFTX, EIKN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/11/2026 (YTD)
How Low Can It Go
| Event | MNPR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -37.0% | -18.8% |
| % Gain to Breakeven | 58.8% | 23.1% |
| Time to Breakeven | 10 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -37.2% | -7.8% |
| % Gain to Breakeven | 59.3% | 8.5% |
| Time to Breakeven | 34 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -60.4% | -9.5% |
| % Gain to Breakeven | 152.7% | 10.5% |
| Time to Breakeven | 94 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -78.7% | -6.7% |
| % Gain to Breakeven | 369.2% | 7.1% |
| Time to Breakeven | 472 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -57.1% | -24.5% |
| % Gain to Breakeven | 132.9% | 32.4% |
| Time to Breakeven | 46 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -54.6% | -33.7% |
| % Gain to Breakeven | 120.4% | 50.9% |
| Time to Breakeven | 2010 days | 140 days |
In The Past
Monopar Therapeutics's stock fell -37.0% during the 2025 US Tariff Shock. Such a loss loss requires a 58.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MNPR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -37.0% | -18.8% |
| % Gain to Breakeven | 58.8% | 23.1% |
| Time to Breakeven | 10 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -37.2% | -7.8% |
| % Gain to Breakeven | 59.3% | 8.5% |
| Time to Breakeven | 34 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -60.4% | -9.5% |
| % Gain to Breakeven | 152.7% | 10.5% |
| Time to Breakeven | 94 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -78.7% | -6.7% |
| % Gain to Breakeven | 369.2% | 7.1% |
| Time to Breakeven | 472 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -57.1% | -24.5% |
| % Gain to Breakeven | 132.9% | 32.4% |
| Time to Breakeven | 46 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -54.6% | -33.7% |
| % Gain to Breakeven | 120.4% | 50.9% |
| Time to Breakeven | 2010 days | 140 days |
In The Past
Monopar Therapeutics's stock fell -37.0% during the 2025 US Tariff Shock. Such a loss loss requires a 58.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Monopar Therapeutics (MNPR)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
AI Analysis | Feedback
- It's like an early-stage Genentech, but specialized in developing several new cancer and supportive care therapies.
- Think of it as a small, independent version of the oncology R&D division of a major pharmaceutical company like Pfizer or Merck.
AI Analysis | Feedback
- Validive: A clonidine hydrochloride mucobuccal tablet in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients.
- Camsirubicin: An analog of doxorubicin in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma.
- MNPR-101: A urokinase plasminogen activator receptor targeted antibody developed for the treatment of various cancers.
- MNPR-101 RIT: A radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19.
- MNPR-202: An analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
AI Analysis | Feedback
As a clinical-stage biopharmaceutical company, Monopar Therapeutics Inc. (MNPR) is engaged in the research and development of therapeutic product candidates. Its lead candidates are currently in Phase 1b or Phase 2b/3 clinical trials. Therefore, Monopar Therapeutics does not currently have major customers for its therapeutic products, as these products are still under development and have not yet been approved for commercial sale to other companies or individual patients.
AI Analysis | Feedback
- NorthStar Medical Radioisotopes, LLC
AI Analysis | Feedback
Chandler D. Robinson, MD MBA MSc – Co-Founder, Chief Executive Officer and Board Member
Dr. Robinson co-founded Monopar Therapeutics and has served as its CEO since its inception in 2014. He previously co-founded and was CEO of Tactic Pharma, where he led the successful sale of its lead compound. He was also a co-founder and board member of Wilson Therapeutics, which was acquired by Alexion (now AstraZeneca). His prior experiences include working in the Nexavar marketing division at Onyx Pharmaceuticals, co-managing a healthcare clinic, and working at Bear Stearns investment bank. Dr. Robinson founded and presides over an undergraduate research-focused non-profit. A compound he researched as an undergraduate at Northwestern University, and published on in Science, completed a Phase III clinical trial for Wilson Disease and is now being advanced to an NDA filing at Monopar.
Quan Vu – Chief Financial Officer
Mr. Vu was appointed Chief Financial Officer of Monopar Therapeutics effective March 3, 2025. He brings over 20 years of experience in corporate and financial strategy, investment banking, and public company management. Mr. Vu has served as a Venture Partner at ZhongMei Capital, an investment firm focused on early-stage biopharmaceutical companies. His previous roles include Chief Financial Officer and Chief Business Officer at Ocugen, Inc., and Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. He also provided consulting services through his firm, Melius BioPharma Consulting, and held leadership positions at Opiant Pharmaceuticals, Inc., Impax Laboratories, Inc., Elevance Health, Inc. (formerly Anthem, Inc.), and Amgen, Inc. His early career involved work in healthcare corporate finance and mergers & acquisitions at Morgan Stanley and Goldman Sachs.
Andrew Cittadine, MBA – Chief Operating Officer
Mr. Cittadine provides leadership and oversight of global operations and business development strategy, leveraging his background in building and selling healthcare businesses. He received his BA, BS, and MS from Stanford and an MBA from Northwestern's Kellogg School of Management.
Andrew P. Mazar, PhD – Co-Founder & EVP, Research & Development
Dr. Mazar is a co-founder of Monopar Therapeutics.
Christopher M. Starr – Co-Founder and Executive Chairman of the Board
Mr. Starr is a co-founder of Monopar Therapeutics and serves as the Executive Chairman of the Board.
AI Analysis | Feedback
Key Risks to Monopar Therapeutics (MNPR)
- Clinical Trial Failure and Inability to Obtain Regulatory Approval: As a clinical-stage biopharmaceutical company, Monopar Therapeutics' business prospects are fundamentally tied to the successful outcome of its ongoing and future clinical trials for product candidates such as Validive (in Phase 2b/3), Camsirubicin (in Phase 1b), MNPR-101, MNPR-101 RIT, and MNPR-202. Biopharmaceutical drug development inherently involves a high risk of failure at various stages of clinical trials due to lack of efficacy, safety concerns, or unforeseen side effects. Furthermore, even with successful trial data, there is no guarantee that regulatory bodies, such as the FDA, will grant marketing approval. The failure of any of its lead product candidates to successfully complete trials or receive regulatory approval would prevent Monopar from commercializing its therapies and generating revenue, which would significantly impact its viability.
- Dependence on External Funding: Monopar Therapeutics currently has no revenue-generating commercialized products and is engaged in costly research and development activities, particularly advanced clinical trials. The company's continued operations and its ability to advance its pipeline are heavily reliant on its capacity to raise substantial additional capital through equity offerings, debt financing, or strategic partnerships. Failure to secure adequate and timely funding could lead to delays, suspension, or termination of its critical development programs, thereby threatening the company's long-term sustainability.
- Competition and Market Acceptance: Should Monopar's product candidates successfully complete clinical trials and receive regulatory approval, they will enter highly competitive markets for the treatment of cancer and severe COVID-19. They will face competition from existing therapies, including established drugs and generic alternatives, as well as new treatments being developed by larger, more established biopharmaceutical companies. The ability to achieve significant market acceptance, establish competitive pricing, and secure favorable reimbursement will be crucial for commercial success, and there is a risk that Monopar's products may not achieve sufficient market share or pricing power to generate substantial revenue.
AI Analysis | Feedback
nullAI Analysis | Feedback
Monopar Therapeutics (MNPR) operates in several distinct therapeutic areas with the following addressable market sizes:
- Validive (for chemoradiotherapy induced severe oral mucositis): The global market for chemotherapy-induced oral mucositis is anticipated to grow from USD 1.35 billion in 2025 to USD 2.20 billion in 2035, exhibiting a compound annual growth rate (CAGR) of 5.3%.
- Camsirubicin (for advanced soft tissue sarcoma): The soft tissue sarcoma market across the top 7 major markets (United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) was valued at USD 2.8 billion in 2024 and is projected to reach USD 5.0 billion by 2035, growing at a CAGR of 5.10%. The global soft tissue sarcoma treatment market size was valued at USD 1,455.12 million in 2024 and is projected to grow to USD 3,910.15 million by 2034, with a CAGR of 10.4%.
- MNPR-101 (urokinase plasminogen activator receptor targeted antibody for various cancers): The global urokinase market size was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.1 billion by 2033, growing at a CAGR of 5.7%. Urokinase-type plasminogen activator receptor (uPAR) is identified as an attractive target for cancer therapies. The global market for Urokinase was estimated at US$1.8 billion in 2024 and is expected to reach US$2.4 billion by 2030, with a CAGR of 4.6%.
- MNPR-101 RIT (radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer): The global radioimmunotherapy market size was estimated at USD 2.68 billion in 2024 and is predicted to surpass approximately USD 12.70 billion by 2034, growing at a CAGR of 16.83%. North America accounts for approximately 45% of the global share.
- MNPR-202 (analog of camsirubicin to potentially treat doxorubicin- and camsirubicin-resistant cancers): The global doxorubicin market was valued at USD 1.8 billion in 2024 and is projected to reach USD 2.6 billion by 2032, with a CAGR of 4.7%. Another estimate indicates the global doxorubicin market size was valued at USD 1.06 billion in 2024 and is projected to grow from USD 1.14 billion in 2025 to reach USD 1.76 billion by 2033, exhibiting a CAGR of 5.6%.
AI Analysis | Feedback
For Monopar Therapeutics (MNPR), the expected drivers of future revenue growth over the next 2-3 years are primarily centered on the progression and potential commercialization of its refocused pipeline, particularly its radiopharmaceutical programs and the recently acquired asset for Wilson Disease.
- Potential FDA Approval and Commercialization of ALXN1840 for Wilson Disease: Monopar Therapeutics assumed full responsibility for the investigational new drug (IND) application for ALXN1840, a treatment for Wilson Disease, from Alexion Pharmaceuticals in June 2025. The company is preparing to submit a New Drug Application (NDA) to the FDA in early 2026. Successful regulatory approval and subsequent commercial launch of ALXN1840 represent a significant near-term revenue growth driver.
- Advancement and Potential Commercialization of MNPR-101-Lu (Therapeutic Radiopharmaceutical): Monopar's therapeutic radiopharmaceutical, MNPR-101-Lu, targets uPAR-expressing advanced or metastatic solid tumors. The FDA cleared its IND application in September 2025, allowing for a Phase 1 dosimetry and dose-escalation trial. Clinical trials are currently active and enrolling patients in Australia, with an Expanded Access Program also active in the U.S. Positive clinical data and progression to later stages could lead to partnerships or eventual market entry within the 2-3 year timeframe or shortly thereafter, generating revenue.
- Progression and Potential Commercialization of MNPR-101-Zr (Imaging Radiopharmaceutical): MNPR-101-Zr is an imaging agent designed to target uPAR in advanced cancer patients. This asset is currently in a first-in-human Phase 1 imaging and dosimetry clinical trial. Successful development and potential approval of this imaging agent could provide revenue through its use in cancer diagnosis and patient selection for uPAR-targeted therapies.
- Strategic Partnerships and Collaborations: As a clinical-stage biopharmaceutical company, Monopar's revenue growth can be significantly driven by securing and expanding strategic partnerships. Collaborations, similar to its ongoing relationship with NorthStar Medical Radioisotopes for radiopharmaceuticals, can provide non-dilutive funding, upfront payments, and milestone payments upon achieving certain development or regulatory objectives. Such partnerships could support the continued development and eventual commercialization of its pipeline assets.
AI Analysis | Feedback
Capital Allocation Decisions for Monopar Therapeutics (MNPR) Over the Last 3-5 Years
Share Repurchases
- In September 2025, Monopar Therapeutics repurchased 550,229 shares of its common stock from Tactic Pharma for $35 million, at a price of $63.6098 per share, using proceeds from a public offering.
Share Issuance
- In September 2025, Monopar completed an underwritten public offering of 1,034,433 shares of common stock and pre-funded warrants to purchase 960,542 shares of common stock, generating approximately $126.9 million in aggregate net proceeds before underwriting discounts and offering expenses.
- In October 2024, the company raised approximately $19.2 million in gross proceeds through a public offering of common stock, priced at $16.25 per share.
- During the nine months ended September 30, 2024, Monopar issued 509,061 shares of common stock under a "Capital on Demand Sales Agreement," raising $3,194,310.
Inbound Investments
- In October 2024, Monopar in-licensed ALXN1840 for Wilson disease from Alexion, AstraZeneca Rare Disease, a deal that included a $4 million upfront cash payment and the issuance of 387,329 shares of common stock to Alexion.
- Monopar strengthened its financial position by raising over $55 million through various public offerings and private placements during the fourth quarter of 2024 and early 2025.
Capital Expenditures
- Research and development (R&D) expenses for the year ended December 31, 2023, were $5.6 million, a decrease from $7.6 million in 2022. This reduction was primarily due to lower costs associated with the Validive and camsirubicin clinical trials, partially offset by increased activity in the MNPR-101 radiopharmaceutical program.
- R&D expenses in the second quarter of 2025 increased to $1,730,000 from $1,130,978 in the second quarter of 2024, mainly driven by higher R&D personnel expenses, including stock-based compensation.
- The company plans to continue investing in its radiopharmaceutical pipeline, including ongoing clinical trials for MNPR-101-Zr and MNPR-101-Lu, and advancing the preclinical MNPR-101-Ac program, with current funds anticipated to support operations at least through December 31, 2027.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Monopar Therapeutics Earnings Notes | 12/16/2025 | |
| Monopar Therapeutics Market Price | 03/21/2025 | |
| Why Monopar Therapeutics Stock Moved: MNPR Stock Has Gained 3935% Since 2023 Fiscal End, Primarily Due To Favorable Change In Revenues | 11/20/2024 | |
| ARTICLES | ||
| Why Did Monopar Stock Swing So Wildly Last Week? | 10/28/2024 |
Trade Ideas
Select ideas related to MNPR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.48 |
| Mkt Cap | 2.3 |
| Rev LTM | 0 |
| Op Inc LTM | -17 |
| FCF LTM | -12 |
| FCF 3Y Avg | -9 |
| CFO LTM | -12 |
| CFO 3Y Avg | -9 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | -3.4% |
| Op Inc Chg 3Y Avg | -23.4% |
| Op Mgn LTM | 38.2% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 34.7% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | 30.4% |
| FCF/Rev 3Y Avg | 17.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.3 |
| P/S | 9.1 |
| P/Op Inc | -12.0 |
| P/EBIT | -10.1 |
| P/E | -9.8 |
| P/CFO | -16.1 |
| Total Yield | -2.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -13.3% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.0% |
| 3M Rtn | -3.7% |
| 6M Rtn | 1.8% |
| 12M Rtn | 1.3% |
| 3Y Rtn | 12.8% |
| 1M Excs Rtn | -8.7% |
| 3M Excs Rtn | -10.1% |
| 6M Excs Rtn | -12.3% |
| 12M Excs Rtn | -30.1% |
| 3Y Excs Rtn | -69.6% |
Price Behavior
Price Behavior
| Market Price | $65.52 | |
| Market Cap ($ Bil) | 0.6 | |
| First Trading Date | 12/19/2019 | |
| Distance from 52W High | -35.8% | |
| 50 Days | 200 Days | |
| DMA Price | $56.37 | $63.24 |
| DMA Trend | up | down |
| Distance from DMA | 16.2% | 3.6% |
| 3M | 1YR | |
| Volatility | 53.7% | 80.5% |
| Downside Capture | 0.10 | 0.80 |
| Upside Capture | 72.44 | 172.27 |
| Correlation (SPY) | 34.2% | 18.8% |
MNPR Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.18 | 1.47 | 1.52 | 1.08 | 1.38 | 1.62 |
| Up Beta | 2.08 | 2.14 | 2.11 | 1.93 | 0.40 | 0.51 |
| Down Beta | 0.13 | 0.59 | 0.17 | -0.77 | 1.10 | 1.24 |
| Up Capture | 80% | 117% | 109% | 70% | 259% | 2306% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 8 | 19 | 29 | 58 | 115 | 355 |
| Down Capture | 715% | 156% | 201% | 170% | 159% | 110% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 13 | 23 | 34 | 65 | 133 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNPR | |
|---|---|---|---|---|
| MNPR | 46.4% | 81.3% | 0.82 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.34 | 12.7% |
| Equity (SPY) | 28.1% | 12.5% | 1.78 | 19.8% |
| Gold (GLD) | 42.9% | 26.9% | 1.30 | 11.1% |
| Commodities (DBC) | 48.6% | 18.0% | 2.14 | -2.5% |
| Real Estate (VNQ) | 13.6% | 13.5% | 0.70 | 12.4% |
| Bitcoin (BTCUSD) | -22.4% | 41.7% | -0.50 | 8.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNPR | |
|---|---|---|---|---|
| MNPR | 17.2% | 295.8% | 0.54 | - |
| Sector ETF (XLV) | 4.8% | 14.6% | 0.15 | 1.3% |
| Equity (SPY) | 12.9% | 17.1% | 0.59 | 4.6% |
| Gold (GLD) | 21.2% | 17.9% | 0.96 | 3.8% |
| Commodities (DBC) | 13.5% | 19.1% | 0.58 | -0.2% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 2.4% |
| Bitcoin (BTCUSD) | 8.5% | 56.0% | 0.36 | 2.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNPR | |
|---|---|---|---|---|
| MNPR | -7.2% | 266.7% | 0.42 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 3.2% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 5.4% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 3.6% |
| Commodities (DBC) | 9.5% | 17.7% | 0.45 | 0.5% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 3.7% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/27/2026 | -0.8% | 1.0% | -1.0% |
| 11/13/2025 | 5.4% | 0.5% | -9.0% |
| 8/12/2025 | 14.6% | 9.3% | 36.9% |
| 3/31/2025 | -9.7% | -25.6% | 4.0% |
| 11/8/2024 | 7.3% | 15.9% | 41.6% |
| 8/9/2024 | -19.6% | -13.8% | -12.7% |
| 3/28/2024 | -7.6% | -13.4% | -10.7% |
| 11/9/2023 | -3.0% | -21.9% | -6.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 5 | 4 |
| # Negative | 10 | 12 | 13 |
| Median Positive | 3.2% | 2.3% | 25.3% |
| Median Negative | -4.7% | -13.7% | -12.7% |
| Max Positive | 14.6% | 15.9% | 41.6% |
| Max Negative | -24.8% | -45.8% | -54.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/27/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/27/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Prior: Q3 2025 Earnings Reported 11/13/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Operational Runway | |||||||
| 2026 Cash Runway | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Vu, Quan Anh | Chief Financial Officer | Direct | Buy | 12292025 | 69.95 | 1,500 | 104,925 | 104,925 | Form |
| 2 | Klausner, Arthur J | Direct | Sell | 12192025 | 67.15 | 5,121 | 343,889 | 588,392 | Form | |
| 3 | Tactic, Pharma Llc | Chief Executive Officer | Direct | Sell | 9262025 | 63.61 | 550,229 | 34,999,957 | 17,303,519 | Form |
| 4 | Tsuchimoto, Kim R | Direct | Sell | 7162025 | 40.00 | 8,904 | 356,171 | 459,454 | Form | |
| 5 | Starr, Christopher M | Direct | Sell | 7162025 | 40.00 | 16,800 | 672,020 | 206,926 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.